Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
A ALIMENTARY TRACT AND METABOLISM
A02 DRUGS FOR ACID RELATED DISORDERS
A02B DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
A02BC Proton pump inhibitors
A02BC04 Rabeprazole
D00724 Rabeprazole sodium (JP18/USP) <JP/US>
USP drug classification [BR:br08302]
Gastrointestinal Agents
Proton Pump Inhibitors
Rabeprazole
D00724 Rabeprazole sodium (JP18/USP)
Therapeutic category of drugs in Japan [BR:br08301]
2 Agents affecting individual organs
23 Digestive organ agents
232 Peptic ulcer agents
2329 Others
D00724 Rabeprazole sodium (JP18/USP)
Drug groups [BR:br08330]
Gastrointestinal agent
DG01975 Agents for peptic ulcer
DG01646 Proton pump inhibitor (PPI)
DG00022 Rabeprazole
D00724 Rabeprazole sodium
Metabolizing enzyme substrate
DG01639 CYP2C19 substrate
DG00022 Rabeprazole
D00724 Rabeprazole sodium
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG00022 Rabeprazole
D00724 Rabeprazole sodium
Drug classes [BR:br08332]
Gastrointestinal agent
DG01646 Proton pump inhibitor (PPI)
D00724 Rabeprazole sodium
Target-based classification of drugs [BR:br08310]
Enzymes
Hydrolases (EC3)
ATPase
ATP4
D00724 Rabeprazole sodium (JP18/USP) <JP/US>
Drugs listed in the Japanese Pharmacopoeia [BR:br08311]
Chemicals
D00724 Rabeprazole sodium
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D00724
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D00724
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D00724
Pharmacogenomic biomarkers [br08341.html]
Polymorphisms and mutations affecting drug response
D00724
